These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22035589)

  • 1. Ataxin-2 polyQ expansions in FTLD-ALS spectrum disorders in Flanders-Belgian cohorts.
    Van Langenhove T; van der Zee J; Engelborghs S; Vandenberghe R; Santens P; Van den Broeck M; Mattheijssens M; Peeters K; Nuytten D; Cras P; De Deyn PP; De Jonghe P; Cruts M; Van Broeckhoven C
    Neurobiol Aging; 2012 May; 33(5):1004.e17-20. PubMed ID: 22035589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study.
    Gijselinck I; Van Langenhove T; van der Zee J; Sleegers K; Philtjens S; Kleinberger G; Janssens J; Bettens K; Van Cauwenberghe C; Pereson S; Engelborghs S; Sieben A; De Jonghe P; Vandenberghe R; Santens P; De Bleecker J; Maes G; Bäumer V; Dillen L; Joris G; Cuijt I; Corsmit E; Elinck E; Van Dongen J; Vermeulen S; Van den Broeck M; Vaerenberg C; Mattheijssens M; Peeters K; Robberecht W; Cras P; Martin JJ; De Deyn PP; Cruts M; Van Broeckhoven C
    Lancet Neurol; 2012 Jan; 11(1):54-65. PubMed ID: 22154785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect.
    Gispert S; Kurz A; Waibel S; Bauer P; Liepelt I; Geisen C; Gitler AD; Becker T; Weber M; Berg D; Andersen PM; Krüger R; Riess O; Ludolph AC; Auburger G
    Neurobiol Dis; 2012 Jan; 45(1):356-61. PubMed ID: 21889984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxin-1 and ataxin-2 intermediate-length PolyQ expansions in amyotrophic lateral sclerosis.
    Conforti FL; Spataro R; Sproviero W; Mazzei R; Cavalcanti F; Condino F; Simone IL; Logroscino G; Patitucci A; Magariello A; Muglia M; Rodolico C; Valentino P; Bono F; Colletti T; Monsurrò MR; Gambardella A; La Bella V
    Neurology; 2012 Dec; 79(24):2315-20. PubMed ID: 23197749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort.
    Van Langenhove T; van der Zee J; Gijselinck I; Engelborghs S; Vandenberghe R; Vandenbulcke M; De Bleecker J; Sieben A; Versijpt J; Ivanoiu A; Deryck O; Willems C; Dillen L; Philtjens S; Maes G; Bäumer V; Van Den Broeck M; Mattheijssens M; Peeters K; Martin JJ; Michotte A; Santens P; De Jonghe P; Cras P; De Deyn PP; Cruts M; Van Broeckhoven C
    JAMA Neurol; 2013 Mar; 70(3):365-73. PubMed ID: 23338682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of 2 Loci at chromosomes 9 and 14 in a multiplex family with frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
    Gijselinck I; Engelborghs S; Maes G; Cuijt I; Peeters K; Mattheijssens M; Joris G; Cras P; Martin JJ; De Deyn PP; Kumar-Singh S; Van Broeckhoven C; Cruts M
    Arch Neurol; 2010 May; 67(5):606-16. PubMed ID: 20457961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Explorative genetic study of UBQLN2 and PFN1 in an extended Flanders-Belgian cohort of frontotemporal lobar degeneration patients.
    Dillen L; Van Langenhove T; Engelborghs S; Vandenbulcke M; Sarafov S; Tournev I; Merlin C; Cras P; Vandenberghe R; De Deyn PP; Jordanova A; Cruts M; Van Broeckhoven C; van der Zee J;
    Neurobiol Aging; 2013 Jun; 34(6):1711.e1-5. PubMed ID: 23312802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations in the PFN1 gene are not a common cause in patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration in France.
    Lattante S; Le Ber I; Camuzat A; Brice A; Kabashi E
    Neurobiol Aging; 2013 Jun; 34(6):1709.e1-2. PubMed ID: 23182804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.
    Hart MP; Gitler AD
    J Neurosci; 2012 Jul; 32(27):9133-42. PubMed ID: 22764223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2.
    Van Damme P; Veldink JH; van Blitterswijk M; Corveleyn A; van Vught PW; Thijs V; Dubois B; Matthijs G; van den Berg LH; Robberecht W
    Neurology; 2011 Jun; 76(24):2066-72. PubMed ID: 21562247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PolyQ repeat expansions in ATXN2 associated with ALS are CAA interrupted repeats.
    Yu Z; Zhu Y; Chen-Plotkin AS; Clay-Falcone D; McCluskey L; Elman L; Kalb RG; Trojanowski JQ; Lee VM; Van Deerlin VM; Gitler AD; Bonini NM
    PLoS One; 2011 Mar; 6(3):e17951. PubMed ID: 21479228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansion.
    Bäumer D; East SZ; Tseu B; Zeman A; Hilton D; Talbot K; Ansorge O
    Acta Neuropathol; 2014 Oct; 128(4):597-604. PubMed ID: 24718895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unconventional features of C9ORF72 expanded repeat in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
    Vatovec S; Kovanda A; Rogelj B
    Neurobiol Aging; 2014 Oct; 35(10):2421.e1-2421.e12. PubMed ID: 24836899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C9orf72 hexanucleotide repeat expansions and Ataxin 2 intermediate length repeat expansions in Indian patients with amyotrophic lateral sclerosis.
    Narain P; Gomes J; Bhatia R; Singh I; Vivekanandan P
    Neurobiol Aging; 2017 Aug; 56():211.e9-211.e14. PubMed ID: 28527524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of long ATXN2 CAG repeat sizes with increased risk of amyotrophic lateral sclerosis.
    Daoud H; Belzil V; Martins S; Sabbagh M; Provencher P; Lacomblez L; Meininger V; Camu W; Dupré N; Dion PA; Rouleau GA
    Arch Neurol; 2011 Jun; 68(6):739-42. PubMed ID: 21670397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis.
    Lee T; Li YR; Chesi A; Hart MP; Ramos D; Jethava N; Hosangadi D; Epstein J; Hodges B; Bonini NM; Gitler AD
    Neurology; 2011 Jun; 76(24):2062-5. PubMed ID: 21562248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype.
    Cooper-Knock J; Shaw PJ; Kirby J
    Acta Neuropathol; 2014 Mar; 127(3):333-45. PubMed ID: 24493408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis.
    Broustal O; Camuzat A; Guillot-Noël L; Guy N; Millecamps S; Deffond D; Lacomblez L; Golfier V; Hannequin D; Salachas F; Camu W; Didic M; Dubois B; Meininger V; Le Ber I; Brice A;
    J Alzheimers Dis; 2010; 22(3):765-9. PubMed ID: 21158017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders.
    Lattante S; Millecamps S; Stevanin G; Rivaud-Péchoux S; Moigneu C; Camuzat A; Da Barroca S; Mundwiller E; Couarch P; Salachas F; Hannequin D; Meininger V; Pasquier F; Seilhean D; Couratier P; Danel-Brunaud V; Bonnet AM; Tranchant C; LeGuern E; Brice A; Le Ber I; Kabashi E;
    Neurology; 2014 Sep; 83(11):990-5. PubMed ID: 25098532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease.
    Lindquist SG; Duno M; Batbayli M; Puschmann A; Braendgaard H; Mardosiene S; Svenstrup K; Pinborg LH; Vestergaard K; Hjermind LE; Stokholm J; Andersen BB; Johannsen P; Nielsen JE
    Clin Genet; 2013 Mar; 83(3):279-83. PubMed ID: 22650353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.